Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647–58.
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCare consortium. Lancet Oncol. 2019;20(1):e29–41.
Article PubMed PubMed Central Google Scholar
Rabiço-Costa D, Gil-da-Costa MJ, Barbosa JP, Bom-Sucesso M, Spratley J. Platinum-drugs ototoxicity in pediatric patients with brain tumors: a 10-year review. J Pediatr Hematol Oncol. 2020;42(1):e25–31.
Winther FO. X-ray irradiation of the inner ear of the guinea pig. Early degenerative changes in the cochlea. Acta Oto-laryngol. 1969;68(1):98–117.
Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the children’s oncology group. Pediatrics. 2010;125(4):e938–50.
Wakisaka H, Yamada H, Motoyoshi K, Ugumori T, Takahashi H, Hyodo M. Incidence of long-term ipsilateral and contralateral ototoxicity following radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx. 2011;38(1):95–100.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339:b2700.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
Article CAS PubMed Google Scholar
Hoaglin DC. Misunderstandings about Q and ‘Cochran’s Q test’ in meta-analysis. Stat Med. 2016;35(4):485–95.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed). 1997;315(7109):629–34.
Lee AW, Ng WT, Hung WM, Choi CW, Tung R, Ling YH, et al. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. Int J Radiat Oncol Biol Phys. 2009;73(4):1121–8.
Ng WT, Ngan RKC, Kwong DLW, Tung SY, Yuen KT, Kam MKM, et al. Prospective, multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(3):630–8.
Paulino AC, Mahajan A, Ye R, Grosshans DR, Okcu MF, Su J, et al. Ototoxicity and cochlear sparing in children with medulloblastoma: proton vs. photon radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;128(1):128–32.
Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(18):1980–90.
You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345–52.
Article PubMed PubMed Central Google Scholar
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349–59.
Article CAS PubMed Google Scholar
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60.
Article PubMed PubMed Central Google Scholar
Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(12):1904–9.
Breivik CN, Nilsen RM, Myrseth E, Pedersen PH, Varughese JK, Chaudhry AA, et al. Conservative management or gamma knife radiosurgery for vestibular schwannoma: tumor growth, symptoms, and quality of life. Neurosurgery. 2013;73(1):48–56.
Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, et al. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). Eur J Cancer (Oxf, Engl: 1990). 2018;103:249–58.
Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: north central cancer treatment group 93–72-52 and southwest oncology group 9503 trials. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(24):3871–9.
Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43(5):959–64.
Article CAS PubMed Google Scholar
Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol Organ Dtsch Rontgenges [et al]. 2018;194(5):375–85.
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(26):3187–93.
Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, et al. Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(11):1163–73.
Kessel KA, Fischer H, Vogel MM, Oechsner M, Bier H, Meyer B, et al. Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma: hearing preservation and patients’ self-reported outcome based on an established questionnaire. Strahlenther Onkol Organ Dtsch Rontgenges [et al]. 2017;193(3):192–9.
Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(4):461–73.
Article CAS PubMed Google Scholar
Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, et al. Ototoxicity of cisplatin plus standard radiation therapy vs accelerated radiation therapy in glioblastoma patients. J Neuro-oncol. 2006;77(3):315–20.
Poon DMC, Kam MKM, Johnson D, Mo F, Tong M, Chan ATC. Durability of the parotid-sparing effect of intensity-modulated radiotherapy (IMRT) in early stage nasopharyngeal carcinoma: a 15-year follow-up of a randomized prospective study of IMRT versus two-dimensional radiotherapy. Head Neck. 2021;43(6):1711–20.
Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):381–90.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60.
Article CAS PubMed PubMed Central Google Scholar
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.
Article CAS PubMed Google Scholar
Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(1):38–47.
Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022;134:106087.
Article CAS PubMed Google Scholar
Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;104(3):286–93.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.
留言 (0)